Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone734-245-1700
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees9
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Gemphire Therapeutics (NASDAQ:GEMP) Frequently Asked Questions
What is Gemphire Therapeutics' stock symbol?
Gemphire Therapeutics trades on the NASDAQ under the ticker symbol "GEMP."
How were Gemphire Therapeutics' earnings last quarter?
Gemphire Therapeutics Inc (NASDAQ:GEMP) posted its quarterly earnings data on Friday, March, 15th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.15. View Gemphire Therapeutics' Earnings History.
When is Gemphire Therapeutics' next earnings date?
What is the consensus analysts' recommendation for Gemphire Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gemphire Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gemphire Therapeutics.
Has Gemphire Therapeutics been receiving favorable news coverage?
Media stories about GEMP stock have been trending positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Gemphire Therapeutics earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for Gemphire Therapeutics.
Are investors shorting Gemphire Therapeutics?
Gemphire Therapeutics saw a increase in short interest in July. As of July 31st, there was short interest totalling 678,400 shares, an increase of 12.4% from the June 30th total of 603,600 shares. Based on an average trading volume of 251,900 shares, the days-to-cover ratio is currently 2.7 days. Approximately 6.6% of the shares of the company are short sold. View Gemphire Therapeutics' Current Options Chain.
Who are some of Gemphire Therapeutics' key competitors?
Some companies that are related to Gemphire Therapeutics include Sierra Oncology (SRRA), Zafgen (ZFGN), Innovate Biopharmaceuticals (INNT), ContraFect (CFRX), DiaMedica Therapeutics (DMAC), AzurRx BioPharma (AZRX), Clearside Biomedical (CLSD), Sophiris Bio (SPHS), Akari Therapeutics (AKTX), Vistagen Therapeutics (VTGN), Aerpio Pharmaceuticals (ARPO), Sernova (SEOVF), Acerus Pharmaceuticals (ASPCF), Sienna Biopharmaceuticals (SNNA) and Citius Pharmaceuticals (CTXR).
What other stocks do shareholders of Gemphire Therapeutics own?
Who are Gemphire Therapeutics' key executives?
Gemphire Therapeutics' management team includes the folowing people:
- Dr. Charles L. Bisgaier, Co-Founder, Chairman & Chief Scientific Officer (Age 65)
- Dr. Steven R. Gullans, CEO, Pres, Director, Principal Financial Officer & Principal Accounting Officer (Age 66)
- Mr. Seth Reno, Chief Commercial Officer (Age 52)
- Mr. Jeffrey S. Mathiesen C.P.A., CPA, Consultant (Age 58)
- Ms. Amy Zaremba Rabourn, Director of Fin.
When did Gemphire Therapeutics IPO?
(GEMP) raised $30 million in an initial public offering on Friday, August 5th 2016. The company issued 3,000,000 shares at a price of $10.00 per share. Jefferies and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.
Who are Gemphire Therapeutics' major shareholders?
Gemphire Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include VHCP Management III LLC (5.59%), BlackRock Inc. (4.54%), VHCP Management II LLC (3.31%) and Vanguard Group Inc. (1.32%). View Institutional Ownership Trends for Gemphire Therapeutics.
Which institutional investors are selling Gemphire Therapeutics stock?
Which institutional investors are buying Gemphire Therapeutics stock?
How do I buy shares of Gemphire Therapeutics?
Shares of GEMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Gemphire Therapeutics' stock price today?
One share of GEMP stock can currently be purchased for approximately $0.5649.
How big of a company is Gemphire Therapeutics?
What is Gemphire Therapeutics' official website?
How can I contact Gemphire Therapeutics?
Gemphire Therapeutics' mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company can be reached via phone at 734-245-1700 or via email at [email protected]
MarketBeat Community Rating for Gemphire Therapeutics (NASDAQ GEMP)
MarketBeat's community ratings are surveys of what our community members think about Gemphire Therapeutics and other stocks. Vote "Outperform" if you believe GEMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
